Live Breaking News & Updates on Viktoria 1

Stay updated with breaking news from Viktoria 1. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Celcuity to Participate in the 6th Annual Evercore ISI

MINNEAPOLIS, Nov. 22, 2023 (GLOBE NEWSWIRE) Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted. ....

United States , Brian Sullivan , Maria Yonkoski , Vicky Hahne , Celcuity Inc , Annual Evercore , Chief Executive Officer , Nasdaq Celc , Elcuity Inc , Breast Cancer , Prostate Cancer , Viktoria 1 ,

HR+/HER2- Breast Cancer: Inhibiting the PI3K/AKT/mTOR Pathway

Dr Vidal expands on use of PI3K/AKT/mTOR pathway inhibitors following frontline progression, focusing on the PI3K inhibitor alpelisib for patients with PIK3CA mutations, as well as capivasertib, an AKT inhibitor in development. ....

Aditya Bardia , Gregory Vidal , Komal Jhaveri , Hr Her2 Breast Cancer , Cdk4 6 Inhibitors , Second Line Therapies , Endocrine Therapy , Endocrine Resistance , Akt Inhibitors , Capitello 291 , Maintain Trial , Ember 3 , Oral Serds , Viktoria 1 ,